C4 Therapeutics, Inc. (CCCC) is a Biotechnology company in the Healthcare sector, currently trading at $2.76. It has a SharesGrow Score of 60/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is CCCC = $7 (+153.6% upside).
Valuation: CCCC trades at a trailing Price-to-Earnings (P/E) of -2.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.23.
Financials: revenue is $36M, +13.1%/yr average growth. Net income is $105M (loss), growing at +5.4%/yr. Net profit margin is -292.1% (negative). Gross margin is 77.8% (+2.2 pp trend).
Balance sheet: total debt is $60M against $257M equity (Debt-to-Equity (D/E) ratio 0.23, conservative). Current ratio is 7.81 (strong liquidity). Debt-to-assets is 16.7%. Total assets: $359M.
Analyst outlook: 10 / 14 analysts rate CCCC as buy (71%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 73/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 85/100 (Pass), Income 10/100 (Fail).
